Research has shown that HTRA2 expression is significantly downregulated in multiple cancers, including gastric, liver, and prostate cancers, a trend that inversely correlates with IAP overexpression and may represent a mechanism for tumor cell survival [61]. This evidence concerns the gene HTRA2 and prostate cancer.